980A695-6.
IPOS COPY.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/12, 15/57, C07K 14/47, C12N 9/64, A61K 38/48, 38/17

A1

(11) International Publication Number: WO 97/32981

(43) International Publication Date: 12 September 1997 (12.09.97)

(21) International Application Number: PCT/GB97/00603

(22) International Filing Date: 4 March 1997 (04.03.97)

(30) Priority Data:

9604865.7	7 March 1996 (07.03.96)	GB
9611896.3	7 June 1996 (07.06.96)	GB
9614293.0	8 July 1996 (08.07.96)	GB
9624028.8	19 November 1996 (19.11.96)	GB

(71) Applicant *(for all designated States except US)*: IMUTRAN LIMITED [GB/GB]; Douglas House, 18 Trumpington Road, Cambridge CB2 2AH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: FARRIES, Timothy, Charles [GB/GB]; The MRC Centre, Hills Road, Cambridge CB2 2QH (GB). HARRISON, Richard, Alexander [GB/GB]; The MRC Centre, Hills Road, Cambridge CB2 2QH (GB).

(74) Agents: WHITE, Martin, Paul et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DOWN-REGULATION RESISTANT C3 CONVERTASE

(57) Abstract

Native complement pathway proteins modified such that the protein is capable of forming a down-regulation resistant C3 convertase. Preferably the modified protein is a modified human C3 protein. DNA sequences encoding such proteins are also provided, together with DNA constructs. Conjugates comprising such proteins and a specific binding moiety, for example an antibody, are also described, as are uses of such proteins and/or conjugates in therapy.